Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.

Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news